Infinity Pharmaceuticals (INFI) Receives Analyst Rating

Infinity Pharmaceuticals (INFI) has an average broker rating of 3, which is interpreted as a Hold, as rated by 7 equity analysts. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Infinity Pharmaceuticals (INFI) : The highest level Infinity Pharmaceuticals (INFI) is projected to reach is $2 for the short term and the lowest estimate is at $1. The consolidated price target from 5 rating analysts who initiate coverage on the stock is $1.6 and the possibility the share price can swing is $0.55.


Also, Morgan Stanley downgrades its view on Infinity Pharmaceuticals (NASDAQ:INFI) according to the research report released by the firm to its investors. The shares have now been rated Equal-weight by the stock experts at the ratings house. Earlier, the shares had a rating of Overweight. Morgan Stanley lowers the price target from $11 per share to $1 per share on Infinity Pharmaceuticals . The rating by the firm was issued on June 15, 2016.

Infinity Pharmaceuticals (NASDAQ:INFI): After opening at $1.38, the stock dipped to an intraday low of $1.37 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $1.42 and the buying power remained strong till the end. The stock closed at $1.4 for the day, a gain of 2.19% for the day session. The total traded volume was 549,686. The stocks close on the previous trading day was $1.37.

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies. In addition to duvelisib, the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies), a worldwide investigation of duvelisib in blood cancers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *